 Baudax Bio, Inc. Baudax or the Company BXRX, a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has commenced an underwritten public offering of its common stock, Series A warrants and Series B warrants. All of the securities in the offering are to be sold by Baudax. Baudax intends to use the net proceeds of the proposed offering for the launch and the commercialization of ANJESOTM, pipeline development activities, and general corporate purposes. 